Modeling Effective AML Therapies - Comparative Anti-Leukemic Synergy of BCL2 and MCL1 Inhibition Combined and with Chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131613
Abstract: Background: Resistance to chemotherapy-induced apoptotic death is a major mechanism responsible for the failure of AML therapies. Levels of anti-apoptotic proteins BCL2 and MCL1 are increased in relapsed AML samples. Venetoclax, a BH3 mimetic that… read more here.
Keywords: synergy; combination; chemotherapy; amg 176 ... See more keywords
Identifying AML patients most likely to benefit from venetoclax using apoptotic gene ratios
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7024
Abstract: Venetoclax is widely used to treat patients with acute myeloid leukemia (AML) who are older or those who are not candidates for intensive chemotherapy. But some patients don't respond well, and it's still hard to… read more here.
Keywords: bcl2l11 pmaip1; gene expression; expression ratios; bcl2 mcl1 ... See more keywords